IPHYF - Innate Pharma S.A. (IPHA) Q4 2023 Earnings Call Transcript
2024-03-21 12:42:06 ET
Innate Pharma S.A. (IPHA)
Q4 2023 Results Conference Call
March 21, 2024 09:00 AM ET
Company Participants
Henry Wheeler - Head, Investor Relations
Herve Brailly - Interim Chief Executive Officer
Sonia Quaratino - Chief Medical Officer
Yannis Morel - Chief Operating Officer
Frederic Lombard - Chief Financial Officer
Arvind Sood - EVP, U.S. Operations
Conference Call Participants
Daina Graybosch - Leerink Partners
Arthur He - H.C. Wainwright
Presentation
Operator
At this time, I would like to welcome everyone to the Innate Pharma Full Year 2023 Financial Results and Business Update Call. Today's conference is being recorded and all lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question-and-answer session. [Operator Instructions]
And I will now turn the conference over to Henry Wheeler, Vice President of Investor Relations. Mr. Wheeler, you may begin.
Henry Wheeler
Thank you. Good morning, good afternoon, and welcome, everyone.
This morning, Innate issued a press release for our full year 2023 financial results and business update. We look forward to highlighting the progress made during the year-to-date as well as addressing future goals and milestones. The press release and today's presentation are both available on the IR section of our website.
On Slide 2, before we start, I'd like to remind you that we'll be making forward-looking statements regarding the financial outlook in addition to regulatory and product plan development. These statements are subject to risks and uncertainties that may cause actual results to differ from those forecasted....
Innate Pharma S.A. (IPHA) Q4 2023 Earnings Call Transcript